44856 Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Katharine Kripke, 

Assistant Director, Vaccine Research 

Program, Division of AIDS, NIAID, NIH, 

6700B Rockledge Dr., Bethesda, MD 

20892–7628, or call non-toll-free 

number 301–402–0846, or E-mail your 

request, including your address to 

NIAIDsurvey@NIH.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: August 25, 2009. 

J.J. McGowan, 

Executive Officer, NIAID, National Institutes 

of Health. 

[FR Doc. E9–20882 Filed 8–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention (CDC) 

Advisory Board on Radiation and 

Worker Health: Notice of Charter 

Renewal 

This gives notice under the Federal 

Advisory Committee Act (Pub. L. 92– 

463) of October 6, 1972, that the 

Advisory Board on Radiation and 

Worker Health, Department of Health 

and Human Services, has been renewed 

for a 2-year period through August 3, 

2011. 

For information, contact Mr. 

Theodore Katz, Executive Secretary, 

Advisory Board on Radiation and 

Worker Health, Department of Health 

and Human Services, 1600 Clifton Road, 

M/S E20, Atlanta, Georgia, 30341, 

telephone 404/498–2533, or fax 404/ 

498–2570. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: August 19, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–20958 Filed 8–28–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln Ave., 

West Allis, WI 53227. 414–328–7840/800– 

877–7016. (Formerly: Bayshore Clinical 

Laboratory.) 

ACM Medical Laboratory, Inc., 160 Elmgrove 

Park, Rochester, NY 14624. 585–429–2264. 

Advanced Toxicology Network, 3560 Air 

Center Cove, Suite 101, Memphis, TN 

38118. 901–794–5770/888–290–1150. 

Aegis Analytical Laboratories, 345 Hill Ave., 

Nashville, TN 37210. 615–255–2400. 

(Formerly: Aegis Sciences Corporation, 

Aegis Analytical Laboratories, Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little Rock, 

AR 72205–7299. 501–202–2783. (Formerly: 

Forensic Toxicology Laboratory Baptist 

Medical Center.) 

Clendo Reference Laboratory, Avenue Santa 

Cruz #58, Bayamon, Puerto Rico 00959. 

787–620–9095. 

Clinical Reference Lab, 8433 Quivira Road, 

Lenexa, KS 66215–2802. 800–445–6917. 

Doctors Laboratory, Inc., 2906 Julia Drive, 

Valdosta, GA 31602. 229–671–2281. 

DrugScan, Inc., P.O. Box 2969, 1119 Mearns 

Road, Warminster, PA 18974. 215–674– 

9310. 

DynaLIFE Dx,* 10150–102 St., Suite 200, 

Edmonton, Alberta, Canada T5J 5E2. 780– 

451–3702/800–661–9876. (Formerly: 

Dynacare Kasper Medical Laboratories.) 

ElSohly Laboratories, Inc., 5 Industrial Park 

Drive, Oxford, MS 38655. 662–236–2609. 

Gamma-Dynacare Medical Laboratories,* A 

Division of the Gamma-Dynacare 

Laboratory Partnership, 245 Pall Mall 

Street, London, ONT, Canada N6A 1P4. 

519–679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053. 504–361– 


cprice-sewell on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices 44857 

8989/800–433–3823. (Formerly: Laboratory 

Specialists, Inc.) 

Kroll Laboratory Specialists, Inc., 450 

Southlake Blvd., Richmond, VA 23236. 

804–378–9130. (Formerly: Scientific 

Testing Laboratories, Inc.; Kroll Scientific 

Testing Laboratories, Inc.) 

Laboratory Corporation of America Holdings, 

7207 N. Gessner Road, Houston, TX 77040. 

713–856–8288/800–800–2387. 

Laboratory Corporation of America Holdings, 

69 First Ave., Raritan, NJ 08869. 908–526– 

2400/800–437–4986. (Formerly: Roche 

Biomedical Laboratories, Inc.) 

Laboratory Corporation of America Holdings, 

1904 Alexander Drive, Research Triangle 

Park, NC 27709. 919–572–6900/800–833– 

3984. (Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of Roche 

Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A Member 

of the Roche Group.) 

Laboratory Corporation of America Holdings, 

1120 Main Street, Southaven, MS 38671. 

866–827–8042/800–233–6339. (Formerly: 

LabCorp Occupational Testing Services, 

Inc.; MedExpress/National Laboratory 

Center.) 

LabOne, Inc. d/b/a Quest Diagnostics, 10101 

Renner Blvd., Lenexa, KS 66219. 913–888– 

3927/800–873–8845. (Formerly: Quest 

Diagnostics Incorporated; LabOne, Inc.; 

Center for Laboratory Services, a Division 

of LabOne, Inc.) 

Maxxam Analytics,* 6740 Campobello Road, 

Mississauga, ON, Canada L5N 2L8. 905– 

817–5700. (Formerly: Maxxam Analytics 

Inc., NOVAMANN (Ontario), Inc.) 

MedTox Laboratories, Inc., 402 W. County 

Road D, St. Paul, MN 55112. 651–636– 

7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 1225 

NE 2nd Ave., Portland, OR 97232. 503– 

413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical Center, 

Forensic Toxicology Laboratory, 1 Veterans 

Drive, Minneapolis, MN 55417. 612–725– 

2088. 

National Toxicology Laboratories, Inc., 1100 

California Ave., Bakersfield, CA 93304. 

661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 1213 

Genoa-Red Bluff, Pasadena, TX 77504. 

888–747–3774. (Formerly: University of 

Texas Medical Branch, Clinical Chemistry 

Division; UTMB Pathology-Toxicology 

Laboratory.) 

Pacific Toxicology Laboratories, 9348 DeSoto 

Ave., Chatsworth, CA 91311. 800–328– 

6942. (Formerly: Centinela Hospital 

Airport Toxicology Laboratory.) 

Pathology Associates Medical Laboratories, 

110 West Cliff Dr., Spokane, WA 99204. 

509–755–8991/800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon Road, 

San Diego, CA 92121. 858–643–5555. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340. 770– 

452–1590/800–729–6432. (Formerly: 

SmithKline Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories.) 

Quest Diagnostics Incorporated, 400 Egypt 

Road, Norristown, PA 19403. 610–631– 

4600/877–642–2216. (Formerly: 

SmithKline Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories.) 

Quest Diagnostics Incorporated, 7600 Tyrone 

Ave., Van Nuys, CA 91405. 866–370–6699/ 

818–989–2521. (Formerly: SmithKline 

Beecham Clinical Laboratories.) 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109. 505–727– 

6300/800–999–5227. 

South Bend Medical Foundation, Inc., 530 N. 

Lafayette Blvd., South Bend, IN 46601. 

574–234–4176 x276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, AZ 

85040. 602–438–8507/800–279–0027. 

St. Anthony Hospital Toxicology Laboratory, 

1000 N. Lee St., Oklahoma City, OK 73101. 

405–272–7052. 

STERLING Reference Laboratories, 2617 East 

L Street, Tacoma, Washington 98421. 800– 

442–0438. 

Toxicology & Drug Monitoring Laboratory, 

University of Missouri Hospital & Clinics, 

301 Business Loop 70 West, Suite 208, 

Columbia, MO 65203. 573–882–1273. 

Toxicology Testing Service, Inc., 5426 NW. 

79th Ave., Miami, FL 33166. 305–593– 

2260. 

U.S. Army Forensic Toxicology Drug Testing 

Laboratory, 2490 Wilson St., Fort George G. 

Meade, MD 20755–5235. 301–677–7085. 

* The Standards Council of Canada (SCC) 

voted to end its Laboratory Accreditation 

Program for Substance Abuse (LAPSA) 

effective May 12, 1998. Laboratories certified 

through that program were accredited to 

conduct forensic urine drug testing as 

required by U.S. Department of 

Transportation (DOT) regulations. As of that 

date, the certification of those accredited 

Canadian laboratories will continue under 

DOT authority. The responsibility for 

conducting quarterly performance testing 

plus periodic on-site inspections of those 

LAPSA-accredited laboratories was 

transferred to the U.S. HHS, with the HHS’ 

NLCP contractor continuing to have an active 

role in the performance testing and 

laboratory inspection processes. Other 

Canadian laboratories wishing to be 

considered for the NLCP may apply directly 

to the NLCP contractor just as U.S. 

laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT 

certify the laboratory (Federal Register, July 

16, 1996) as meeting the minimum standards 

of the Mandatory Guidelines published in the 

Federal Register on April 13, 2004 (69 FR 

19644). After receiving DOT certification, the 

laboratory will be included in the monthly 

list of HHS-certified laboratories and 

participate in the NLCP certification 

maintenance program. 

Elaine Parry, 

Director, Office of Program Services, 

SAMHSA. 

[FR Doc. E9–20932 Filed 8–28–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

Coordinating Center for Health 

Promotion (BSC, CCHP or the BSC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 1 p.m.–5 p.m., September 

15, 2009. 

The call may end before 5 p.m. if business 

is completed. Someone will remain on the 

line until that time to notify callers that the 

call is ended and business complete. 

Place: Teleconference originating from 

CDC, 1825 Century Boulevard, NE., Room 

4066, Atlanta, Georgia 30345. 

Call-in number: (800) 779–9076. 

Participant pass code: 39780. 

If you have a problem in accessing the call, 

call (404) 498–6700. 

Status: This meeting is open to the public 

via the conference line above which will 

accommodate approximately 100 callers. 

Purpose: This BSC is charged with 

providing advice and guidance to the 

Secretary of Health and Human Services, the 

Director of CDC, and the Director of CCHP 

concerning strategies and goals for the 

programs and research within the National 

Center on Birth Defects and Developmental 

Disabilities and the National Center for 

Chronic Disease Prevention and Health 

Promotion. 

Matters To Be Discussed: The agenda will 

include a continuation of the discussion and 

finalization of recommendations to CDC 

leadership as prescribed in the Coordinating 

Center for Health Promotion Charter. Those 

recommendations relate to strategic planning 

for the National Center on Birth Defects and 

Developmental Disabilities as well as the 

results of the BSC’s review of the National 

Center for Chronic Disease Prevention and 

Health Promotion as an organizational unit at 

CDC. 

Providing Oral or Written Comments: It is 

the policy of the BSC, CCHP to provide a 

brief period for oral public comments. In 

general, each individual or group requesting 

to make an oral presentation will be limited 

to a total time of five minutes, if time 

permits. 

Contact Person for Additional Information: 

Karen Steinberg, PhD, Senior Science Officer, 

Coordinating Center for Health Promotion, 

CDC, 4770 Buford Highway, NE., Mailstop E– 

70, Atlanta, Georgia 30341; telephone (404) 

498–6700; fax (404) 498–6880; or via e-mail 

at Karen.Steinberg@cdc.hhs.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

CDC and the Agency for Toxic Substances 

and Disease Registry. 


cprice-sewell on DSK2BSOYB1PROD with NOTICES